Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SR-T100 Gel in Common Warts
NCT01796795Phase 2Suspended
- Sponsor
- G&E Herbal Biotechnology
- Start
- Sep 2030
- Primary completion
- Apr 2033
- Modality
- Transdermal Patches, Hydrogel Systems, Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of SR-T100 in common warts (3 arms), sponsored by G&E Herbal Biotechnology. Primary endpoint: Total clearance rate of treated Common Warts at 16 weeks. Planned start Sep 2030; status: suspended.
02
Drugs
SR-T100
03
Conditions
common warts
Beyond the preview
Go deeper on NCT01796795.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01796795.